Table 1.
Hematological parameters and mutational status of patients and demographic characteristics of controls and patients.
| CTRL | ET | PMF | PV | |
|---|---|---|---|---|
| Age (years) – n (range) | 57.2 (31–83) | 54 (20–81) | 65 (44–80) | 63 (39–83) |
| Gender – n (%) | ||||
| Male | 14 (42) | 5 (55) | 13 (76) | 9 (39) |
| Female | 20 (58) | 4 (44) | 4 (23) | 14 (60) |
| JAK2 V617F carriers – n (%) | – | 5 (55) | 12 (70) | 17 (74) |
| Hemoglobin (g/dL) – n (range) | – | 13.01 (10.1–17.1) | 11.47 (5.88–17.4) | 14.95 (9.9–21.5) |
| Platelets (× 103/μL) – n (range) | – | 818 (399–1293) | 334 (38.5–1474) | 425 (161–772) |
| WBC (× 106/L) – n (range) | – | 9.02 (3.96–15.6) | 11.71 (1.46–31.4) | 10.21 (3.6–21.3) |
CTRL: control (healthy subjects); ET: essential thrombocythemia; PMF: primary myelofibrosis; PV: polycythemia vera; WBC: white blood cell count.